TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01924819
Drug: Epirubicin + cisplatin + 5-fluorouracil OR epirubicin + cisplatin + capecitabine OR epirubicin + oxaliplatin + capecitabine OR 5-Fluorouracil + leucovorin + oxaliplatin + docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 50 mg/m2 IV day 1, cisplatin 60 mg/m2 IV day 1, 5-fluorouracil 200 mg/m2/d IV 21 day continuous infusion (ECF chemotherapy).~Epirubicin 50 mg/m2 IV day 1, Cisplatin 60 mg/m2 IV day 1, Capecitabine (X = Xeloda) 625mg/m2, bid days 1-21 (ECX chemotherapy)~Epirubicin 50mg/m2 IV day 1, Oxaliplatin (O) 130mg/m2 IV day 1, Capecitabine 625mg/m2, bid days 1-21 (EOX chemotherapy)~5-Fluorouracil 2600 mg/m² IV 24 h infusion day 1, Leucovorin (L) 200 mg/m² IV day 1, Oxaliplatin 85 mg/m² IV day 1, Docetaxel (T) 50 mg/m² IV day 1 (FLOT chemotherapy)
Study: NCT04042974
Drug: vaginal dinoprostone
Normalized name: dinoprostone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
Study: NCT04042974
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
Study: NCT03656926
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care Therapy. Eligible patients should be on a maintenance regimen of immunosuppressive agents including tacrolimus, a second agent such as but not limited to MMF or azathioprine, and a systemic corticosteroid such as prednisone as third agent. The regimen must be stable within 4 weeks prior to randomization with respect to the therapeutic agents. Patients receiving azithromycin for prophylaxis or treatment of BOS, must be on a stable regimen for a least 4-weeks prior to randomization and will continue to receive azithromycin during the trial as deemed appropriate by the investigator
Study: NCT00923195
Drug: MART-1: 26-35(27L) Peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14.
Study: NCT00923195
Drug: gp100:154-162 Peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14.
Study: NCT00923195
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day -6 to -5: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna15 mg/kg/day over 1 hr X 2 days.
Study: NCT01613131
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical, .06%, Applied once daily for 50 days.
Study: NCT01613131
Drug: Placebo Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Gel, Applied once daily for 50 days, Placebo comparator.
Study: NCT02516631
Drug: Angusta™
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of Angusta™ (25 µg) given every 2 hours
Study: NCT02516631
Drug: Cytotec®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1/8 of a tablet of Cytotec® (25 µg) given every 2 hours. Drug administration should be repeated every 2 hours until labour has commenced.
Study: NCT02516631
Drug: Angusta™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets of Angusta™ 25 µg given every 4 hours
Study: NCT02516631
Drug: Cytotec®
Approvals — FDA: no, EMA: no, PMDA: no
Description: ¼ of a tablet of Cytotec® given every 4 hours. Drug administration should be repeated every 4 hours until labour has commenced.
Study: NCT02516631
Drug: Angusta™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets of Angusta™ (total dose of 50 µg), given every 4 hours
Study: NCT02516631
Drug: Cytotec®
Approvals — FDA: no, EMA: no, PMDA: no
Description: ¼ of a tablet of Cytotec® (50 µg), given every 4 hours. Subjects should not swallow for a period of 5 minutes. Drug administration should be repeated every 4 hours until labour has commenced.
Study: NCT01526122
Drug: G0041(75/100mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G0041(75/100mg) 2 capsules(Clopidogrel 75mg \& Aspirin 100mg in 1 capsule), PO
Study: NCT03739840
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be provided matching padsevonil.
Study: NCT00830063
Drug: naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen 1000 mg daily for 16 weeks
Study: NCT00048061
Drug: Ibandronate [Bonviva/Boniva]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5mg po daily
Study: NCT00048061
Drug: Ibandronate [Bonviva/Boniva]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg po monthly on a single day
Study: NCT00048061
Drug: Ibandronate [Bonviva/Boniva]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg po monthly over 2 consecutive days
Study: NCT00048061
Drug: Ibandronate [Bonviva/Boniva]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg po monthly
Study: NCT00380913
Drug: Cesamet™ (nabilone)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01269593
Drug: PET Imaging using 124 IPUH71
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dose of up to 11.0 mCi (range: 4.0-11.0 mCi) of 124I-PUH71 will be administered intravenously with the patient at rest. 124I-PUH71 scans will be performed at immediately and/or 3-4 hours, 20-24 hours, and 40-80 hours after injection of the radiotracer. Optionally, in willing patients scans will be performed 160-200 hours (\~7-8 days) after injection of the radiotracer. At each time-point, a 45-60 minute axial body image is acquired. Images will be acquired on a state-of-the-art PET-CT scanner. A low-dose CT will be obtained immediately-prior to PET imaging, at each time-point. A 30-45 minute scanning timeperiod is typical for clinical PET studies.
Study: NCT01795703
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone will be administered orally as 5 mg tablets twice daily for 28-daily dosing cycle which will be continued until disease progression or unacceptable toxicity.
Study: NCT00416403
Drug: fluvastatin sodium
Normalized name: Fluvastatin Sodium
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT04408313
Drug: XR-NTX
Normalized name: Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable naltrexone will be used, at a dose of 4cc (380mg of naltrexone), administered by intramuscular injection to the buttocks (alternating sides monthly). Individuals will receive monthly injections.
Study: NCT03165890
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
Study: NCT02370784
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral drug of similar appearance to atorvastatin
Study: NCT02140164
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dose of 100 mg (or appropriate weight-adjusted pediatric dose) of minocycline twice daily for 12 months.
Study: NCT00689403
Drug: AZD1305
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended release capsules, oral single doses
Study: NCT01828515
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01828515
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants receive 160 mg x 4 days after vilazodone or placebo pre-treatment
Study: NCT00004686
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00136019
Drug: SPM 927
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01236014
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo \& standard of care
Study: NCT03053271
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the 4-week randomized withdrawal period, subjects will be dosed for 4 weeks with placebo that matches the same ATR-101 dose level being used at the completion of the open-label dose-escalation period.
Study: NCT00666796
Drug: Placebo ethanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo ethanol 0.4% in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
Study: NCT00666796
Drug: Ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol 0.7 g/kg in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
Study: NCT00666796
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo oral capsule with 8 oz of water 2 hours prior to assessment timepoint
Study: NCT03435614
Drug: Opioids
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once an opioid dose reduction of 10% or greater is achieved, a daily assessment will be conducted by a physician using the DSM-5 criteria for opioid withdrawal. In addition, signs and symptoms of withdrawal will be collected daily by a blinded investigator.
Study: NCT02594332
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02331875
Drug: IPH2201
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first 6 patients will receive IPH2201, IV, at a dose of 4 mg/kg q2w x 4. Subsequent patients will be treated at a dose of 10 mg/kg q2w x 4.
Study: NCT00276913
Drug: STA-5312
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00558155
Drug: peptisorb
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard isocaloric eteral diet (1 ml = 1 kcal)
Study: NCT00558155
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein requirements were covered by 10 and 15% amino acid solutions (Aminoplasmal, B Braun, Poland). Energy requirements were covered by glucose (10, 20 and 40% solutions, B Braun, Poland) and lipid emulsions (10 and 20% Lipofundin MCT/ LCT, B Braun, Poland). Addtional: Tracutil, Addamel
Study: NCT00558155
Drug: Omegaven, Dipeptiven
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunostimulating components: Omegaven (omega-3-fatty acids) and Dipeptiven (Glutamine Arginine) Protein requirements were covered by 10 and 15% amino acid solutions (Aminoplasmal, B Braun, Poland). Energy requirements were covered by glucose (10, 20 and 40% solutions, B Braun, Poland) and lipid emulsions (10 and 20% Lipofundin MCT/ LCT, B Braun, Poland). Addtional: Tracutil, Addamel
Study: NCT03029741
Drug: AZD0284
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single oral dose of 4 to 120 mg AZD0284 oral suspension 5 mg/mL in the fasted state
Study: NCT03029741
Drug: [14C]AZD0284
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following administration of the AZD0284 oral suspension subjects will receive an IV infusion of 20 μg \[14C\]AZD0284 solution
Study: NCT04455243
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered in the same schedule and volume as NAC
Study: NCT04541290
Drug: Protopic 0.1 % Topical Ointment
Normalized name: Protopic 0.1 % Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied in a thin layer covering all of the arm including the armpit and hand once a day for six months
Study: NCT01033526
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-2 tablets matching Placebo as needed every 4-6 hours over a maximum of 5 days
Study: NCT00884325
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet taken orally at night for 28 days
Study: NCT01540825
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder for oral solution
Study: NCT03939637
Drug: Steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone/Prednisolone 4mg/kg/day (Max 120 mg/day) x 4 day
Study: NCT03800693
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03800693
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00276705
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00276705
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02569827
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Q6H for 5 days
Study: NCT02071381
Drug: DW1030 75mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02248337
Drug: Colon preparation for colonoscopy
Normalized name: Sus scrofa colon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colon cleansing prior to perform colonoscopy
Study: NCT00002747
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04255927
Drug: Coated Vicryl plus
Normalized name: VICRYL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicryl plus (Coated Polyglactin 910 with Triclosan)
Study: NCT04255927
Drug: Coated vicryl
Normalized name: VICRYL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicryl (Coated Polyglactin 910 without Triclosan)
Study: NCT02288247
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT02288247
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT04537819
Drug: Imupret in addition to local NAID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional prescription of Imupret oral drops to conventional therapy with local NAID (Benzydamine hydrochloridy), elimination of irritating factors in the diet and acetaminophen (if necessary)
Study: NCT04537819
Drug: Local NAID (Benzydamin)
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: (Benzydamine hydrochloridy) and acetaminophen (if necessary), elimination of irritating factors in the diet
Study: NCT00004187
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00877474
Drug: PM01183
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vials containing 0.2 mg of PM01183 as powder for concentrate for solution for infusion
Study: NCT04229004
Drug: Drug: Dose -SM-88
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm is closed to recruitment.~460 mg (2 capsules) twice daily of a 28-day cycle along with the administration of methoxsalen, phenytoin and sirolimus.
Study: NCT01100736
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets taken twice daily, orally, for 7 days (placebo arm) or once daily for 7 days (sitaxsentan arm)
Study: NCT03837626
Drug: Placebo - Cap
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of 1 pill a day
Study: NCT03837626
Drug: Amiloride Pill
Normalized name: amiloride Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Max dose of 5 mg a day for 6 months
Study: NCT02162849
Drug: Placebo Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting on Day 8, and then every day after that, participant applies 1 placebo patch each day for 11 weeks.
Study: NCT02162849
Drug: Placebo Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant takes placebo tablet 1-10 days after Visit 1. On Days 1-3, participant takes 1 dose of the placebo each morning. Starting on Day 4, and then every day after that, participant takes 1 dose in the morning and 1 dose in the evening.
Study: NCT02342366
Drug: GHB 35 mg/kg p.o.
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB 35 mg/kg p.o.
Study: NCT02342366
Drug: GHB 20 mg/kg p.o.
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB 20 mg/kg p.o.
Study: NCT04663737
Drug: SOC
Normalized name: Isocet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Some therapeutics for COVID-19 are available through EUA. SOC treatment availability is expected to change during the course of this trial.
Study: NCT01364623
Drug: Low dose testosterone nasal gel, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose testosterone nasal gel, single dose
Study: NCT01364623
Drug: Medium dose testosterone nasal gel, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose testosterone nasal gel, single dose
Study: NCT01364623
Drug: High dose testosterone nasal gel, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose testosterone nasal gel, single dose
Study: NCT01364623
Drug: Medium dose testosterone nasal gel, multiple dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose testosterone nasal gel, multiple dose
Study: NCT05673772
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 85 mg/m2, Levoleucovorin 200mg (or Leucovroin, Leucosodium 400mg)/m2, 5- FU 400 mg/m2, and continuous 5- FU 2,400 mg/m2 for 46 hours
Study: NCT03587662
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03587662
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04148183
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: We add Placebo, treatment was administered for 8 weeks
Study: NCT02057341
Drug: ARRY-371797, p38 inhibitor; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple dose, single schedule
Study: NCT03875391
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo nasal spray
Study: NCT03543033
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: These subjects will first receive a topical anesthesia to the skin and underlying tissue in a maximum amount of 5 ml of 1% Lidocaine. Following this application, an 18-20 gauge epidural needle will be used to inject a solution containing 80 mg Depo-Medrol in 1 ml of 1% PF Lidocaine and 5ml of sterile PF saline
Study: NCT03627182
Drug: CKD-501 0.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with D150 and D745
Study: NCT03627182
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, orally, 1 tablet once a day for 24weeks with D150 and D745.~CKD-501 placebo will be changed to CKD-501 from extension stydy to EOS(end of study).
Study: NCT00397839
Drug: Ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate orally (tablet) at a dose of 150 mg once per month
Study: NCT00397839
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally (tablet) at a dose of 150 mg once per month
Study: NCT03809923
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received 20 ml normal saline and 20 ml normal saline in the CON group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion 20 ml normal saline and 20 ml normal saline every hour until 30 min before the end of surgery
Study: NCT01712321
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching Vilazodone 20mg or 40mg, taken once daily by mouth
Study: NCT01353508
Drug: LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg and 400 mg tablets
Study: NCT00670358
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00670358
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00613106
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 800mg administered orally 3 times daily for at least 28 weeks
Study: NCT02952040
Drug: ASP1517
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose
Study: NCT01497145
Drug: KRN321
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03586830
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo to JNJ-64565111 SC once-weekly until Week 12.
Study: NCT03872700
Drug: Intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl Citrate
Study: NCT01284595
Drug: [14C] AZD8931
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 160 mg oral dose administered on Day 1
Study: NCT03204786
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Nasal Spray
Study: NCT04164069
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04164069
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04164069
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02619994
Drug: Locally-used WHO-approved MDR-TB regimen in Korea
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03314454
Drug: Beer
Normalized name: Beer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common brands beer with similar calorie (125-150) and alcohol level (approximately 4.5% ABV)
Study: NCT02068339
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002898
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02524197
Drug: CR845 0.25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will dose orally twice a day with CR845 0.25 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.